Oak Hill Bio and Chiesi Group have commenced the Phase 2b clinical study for the investigational drug OHB-607, targeting the prevention of bronchopulmonary dysplasia in extremely premature infants, with the first patient now enrolled in Europe.

Oak Hill Bio is a clinical-stage neonatology and rare disease therapeutics company developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases.

www.oakhillbio.com

Therapeutics

Biotechnology

Health Care

Cambridge

Oak Hill Bio

Oak Hill Bio and Chiesi Group announce enrollment of the first European patient in a Phase 2b clinical study for OHB-607 aimed at preventing bronchopulmonary dysplasia in premature infants.

Oak Hill Bio and Chiesi Group announce enrollment of the first European patient in a Phase 2b clinical study for OHB-607 aimed at preventing bronchopulmonary dysplasia in premature infants.

Product Description

Company Information

Product Launch Insights

Related People

Oak Hill Bio and Chiesi Group announce enrollment of the first European patient in a Phase 2b clinical study for OHB-607 aimed at preventing bronchopulmonary dysplasia in premature infants.

Product Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Product Launch Insights

Related People

Company Information